What is the difference between DSIP and Noopept?

DSIP: DSIP (Delta Sleep Inducing Peptide) is a nonapeptide (9 amino acids) first isolated from rabbit thalamus in 1974, initially believed to directly induce slow-wave (delta) sleep. Research has since broadened its profile considerably: it modulates the HPA axis (reducing stress-driven cortisol), influences GH and LH release, demonstrates antioxidant properties, and may have cardioprotective effects. Despite decades of research, its precise receptor system remains incompletely characterized. Noopept: Dipeptide-derived nootropic developed in Russia and used across Eastern Europe as a cognitive enhancer and neuroprotective agent. Structurally related to piracetam but estimated to be approximately 1000× more potent by weight. Rapidly crosses the blood-brain barrier and is hydrolyzed to the endogenous neuropeptide cycloprolylglycine, which is proposed as its primary active metabolite. Both are in the Nootropic & Cognitive category but differ in mechanism, dosing, and research evidence — see the full comparison.

Can you take DSIP and Noopept together?

There is no specific, well-documented interaction rule for combining DSIP and Noopept in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, DSIP or Noopept?

DSIP is currently research-stage and Noopept is research-stage. "Better researched" depends on your research goal — review each profile's cited sources.

Nootropic & Cognitive · Comparison

DSIP vs Noopept

A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

DSIP

Research-stage

DSIP (Delta Sleep Inducing Peptide) is a nonapeptide (9 amino acids) first isolated from rabbit thalamus in 1974, initially believed to directly induce slow-wave (delta) sleep. Research has since broadened its profile considerably: it modulates the HPA axis (reducing stress-driven cortisol), influences GH and LH release, demonstrates antioxidant properties, and may have cardioprotective effects. Despite decades of research, its precise receptor system remains incompletely characterized.

Full profile

Noopept

Research-stage

Dipeptide-derived nootropic developed in Russia and used across Eastern Europe as a cognitive enhancer and neuroprotective agent. Structurally related to piracetam but estimated to be approximately 1000× more potent by weight. Rapidly crosses the blood-brain barrier and is hydrolyzed to the endogenous neuropeptide cycloprolylglycine, which is proposed as its primary active metabolite.

Full profile

	DSIP	Noopept
Category	Nootropic & Cognitive	Nootropic & Cognitive
Also known as	Delta Sleep Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu	GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, omberacetam, N-Phenylacetyl-L-Prolylglycine Ethyl Ester
Evidence	Research-stage	Research-stage
Dosing range	100mcg–500mcg mcg, Once daily (evening) or every other day	5mg–20mg mg, 1–3x daily oral or sublingual (8–12 week cycles)
Administration	Subcutaneous injection, Intranasal, Intravenous (clinical studies)	Oral (capsule/powder), Sublingual (dissolved under tongue), Intranasal
Key side effects	Generally well-tolerated, Daytime drowsiness if dosed in morning, Mild headache, Altered dream quality (common)	Headache (especially without choline supplementation), Irritability, Brain fog at high doses, Insomnia (if taken too late in day)
Cited sources	3 references	2 references

Key differences

Administration: DSIP — Subcutaneous injection, Intranasal, Intravenous (clinical studies); Noopept — Oral (capsule/powder), Sublingual (dissolved under tongue), Intranasal.
Dosing units differ: DSIP is dosed in mcg, Noopept in mg — they operate at different scales.
Frequency: DSIP is typically Once daily (evening) or every other day; Noopept is 1–3x daily oral or sublingual (8–12 week cycles).
Research depth: this profile cites 3 sources for DSIP vs 2 for Noopept.

How each works

DSIP

DSIP does not directly trigger sleep in the simple sense originally proposed — more recent research indicates it modulates the neuroendocrine environment that facilitates sleep. Key findings: it reduces ACTH-driven cortisol elevation under stress, increases GH secretion in some models, and attenuates withdrawal severity in opioid and alcohol dependence (mechanisms unclear). DSIP demonstrates antioxidant effects and has cardioprotective properties in ischemic preconditioning models in animals. Its unique resistance to most peptidases (attributed to its unusual conformation) gives it a relatively long half-life for a nonapeptide.

Noopept

Noopept (GVS-111) enhances AMPA-receptor function and increases expression of BDNF and NGF in the hippocampus and basal forebrain. Its active metabolite cycloprolylglycine acts as an endogenous neuropeptide with anxiolytic and cognition-enhancing properties. Russian clinical trials demonstrate cognitive improvement in subjects with cognitive impairment, with a better tolerability profile than piracetam at equipotent doses.

Read the full DSIP profile Read the full Noopept profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.